Please assess the completion status of the following clinical trial:

Trial Title: forREAL: FORXIGA PRESCRIPTION EVENT MONITORING PROGRAM (PEMP)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients with Type 2 Diabetes who are:~* Prescribed Forxiga for glycaemic management AND~* Who have the ability to provide informed consent~Exclusion Criteria:~Patients with whom use of Forxiga is contraindicated:~* Patients with Type 1 Diabetes~* Patients with moderate to severe renal impairment \[Creatinine clearance (CrCl) \<60 mL/min or estimated glomerular filtration rate (eGFR) \<60mL/min/1.73m²\]~Additional exclusion criteria:~* Age \>75 years~* Concomitant use of loop diuretics or pioglitazone~* Patients who are currently on another SGLT2 inhibitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- T2DM patients newly prescribed Forxiga (Type: None): A post-marketing evaluation of the safety of Forxiga (10 mg tablets, orally once daily for 6 months) through an observational prescription adverse event monitoring program (registry-based monitoring program) is warranted to assess real-world incidence of adverse events in routine clinical practice.

Based on this trial design, predict the completion outcome and termination type (if applicable).